{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:04:49Z","timestamp":1759017889597,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lilly Suzhou Pharmaceutical Company Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clinthera.2019.08.003","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:36:45Z","timestamp":1568014605000},"page":"2057-2065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Ke","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Strizek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Boye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuli","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinthera.2019.08.003_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia"},{"year":"2017","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","key":"10.1016\/j.clinthera.2019.08.003_bib2"},{"issue":"12","key":"10.1016\/j.clinthera.2019.08.003_bib3","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"issue":"21","key":"10.1016\/j.clinthera.2019.08.003_bib4","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clinthera.2019.08.003_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/dme.12137","article-title":"Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK","volume":"30","author":"Hall","year":"2013","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.clinthera.2019.08.003_bib6","first-page":"4","article-title":"Chinese guideline for type 2 diabetes mellitus","volume":"10","author":"Chinese Diabetes Society","year":"2018","journal-title":"Chin J Diabetes"},{"issue":"2","key":"10.1016\/j.clinthera.2019.08.003_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/1753-0407.12165","article-title":"China type 2 diabetes treatment status survey of treatment pattern of oral drugs users","volume":"7","author":"Ji","year":"2015","journal-title":"J Diabetes"},{"issue":"9","key":"10.1016\/j.clinthera.2019.08.003_bib8","doi-asserted-by":"crossref","first-page":"e39513","DOI":"10.1371\/journal.pone.0039513","article-title":"Medical care and payment for diabetes in China: enormous threat and great opportunity","volume":"7","author":"Yang","year":"2012","journal-title":"PloS One"},{"issue":"16","key":"10.1016\/j.clinthera.2019.08.003_bib9","first-page":"2461","article-title":"Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone","volume":"124","author":"Zhang","year":"2011","journal-title":"Chin Med J"},{"issue":"12","key":"10.1016\/j.clinthera.2019.08.003_bib10","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.clinthera.2017.11.001","article-title":"Characteristics associated with the choice of first injectable therapy among us patients with type 2 diabetes","volume":"39","author":"Yu","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.08.003_bib11","series-title":"R: A language and environment for statistical computing","first-page":"201","author":"R Core Team","year":"2013"},{"issue":"4","key":"10.1016\/j.clinthera.2019.08.003_bib12","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"10","key":"10.1016\/j.clinthera.2019.08.003_bib13","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.clinthera.2019.08.003_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.clinthera.2019.08.003_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.clinthera.2019.08.003_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/dmrr.2541","article-title":"Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)","volume":"30","author":"Pan","year":"2014","journal-title":"Diabetes\/Metabolism Res Rev"},{"issue":"3","key":"10.1016\/j.clinthera.2019.08.003_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.clinthera.2019.08.003_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/PPA.S122556","article-title":"Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care system","volume":"11","author":"Barba","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2019.08.003_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2019.01.006","article-title":"Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings","author":"Guerci","year":"2019","journal-title":"Diabetes Metab"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:03Z","timestamp":1758963063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0149291819303972"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}